Alkhafaji, Silver http://orcid.org/0000-0002-2248-1381
Wolf, Denise M.
Magbanua, Mark Jesus M. http://orcid.org/0000-0003-2113-3593
J. van ‘t Veer, Laura http://orcid.org/0000-0002-9838-8298
Park, John W.
Esserman, Laura http://orcid.org/0000-0001-9202-4568
Mukhtar, Rita A. http://orcid.org/0000-0001-8079-7846
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08CA256047)
Article History
Received: 5 May 2023
Accepted: 15 February 2024
First Online: 26 February 2024
Competing interests
: Dr. Laura J. van ‘t Veer is a part-time employee and stockholder of Agendia. Dr. John W. Park reports honoraria from Roche, Gilead, AstraZeneca, and Daiichi Sankyo. Dr. Laura Esserman reported that she is on the Blue Cross Medical advisory panel, is paid for travel, and is given an honorarium for her time; she is also an uncompensated board member of the Quantum Leap Healthcare Collaborative, which sponsors the I-SPY trial; she leads an investigator-initiated vaccine trial for high-risk ductal carcinoma in situ, which is funded by Merck through the University of California, San Francisco. No potential conflicts of interest were disclosed by the other authors.